Evofem Biosciences, Inc. (OTCPK: EVFM)
Health Care · Pharmaceuticals · US
$0.01
-0.32% today · -23.6% 1Y
Evofem Biosciences, Inc. (OTCPK: EVFM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $993.98K and employs 29 people.
Over the last twelve months the share price has lost 23.6%, trading between 0.00 and 0.02.
Tweenvest scores Evofem Biosciences, Inc. across four factors: quality 28/100, value 62/100. Its strongest factor is value.
EVFM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $993.98K
- Revenue (TTM)
- $18.05M
- P/E
- —
- EPS
- -0.12
- Dividend yield
- —
- Beta (5Y)
- -1.34
- 52-week high
- $0.02
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 132.53M
- Employees
- 29
- Next earnings
- —
About Evofem Biosciences, Inc.
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
- ISIN
- US30048L3024
- Listed since
- Nov 20, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,262.11 | +1.22% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.40 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.45 | +2.52% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.60 | +0.86% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £123.85 | +2.27% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.42 | +1.61% |
Figures last refreshed Aug 18, 2026.